Prednisone FDA label update (2026-08-20)

2 min read Aug 25, 2026, 9:11 PM

Medications Prednisone Corticosteroids Steroids Osteoporosis Anemia Regulatory Update Adult patients

Why This Matters

Prednisone is commonly used short-term in IBD flares; an FDA label update clarifies approved uses and dosing considerations that affect how clinicians prescribe it and how patients should take and stop the drug.

Who Should Pay Attention

Adult patients with IBD (Crohn’s disease or ulcerative colitis), caregivers, and clinicians who prescribe or manage corticosteroid therapy.

Study Snapshot

Story typeRegulatory

Evidence typeRegulatory update

Study statusHuman prescription drug

Source depthRegulatory record

What To Know

This DailyMed entry is an FDA drug-label update for prednisone (prescription corticosteroid). It lists approved indications, dosing guidance, and administration cautions such as taking in the morning, individualized dosing (5–60 mg/day), gradual tapering after long-term use, and general warnings about not stopping abruptly.

The label includes gastrointestinal, endocrine, rheumatic, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, and gastrointestinal disease indications — explicitly naming ulcerative colitis and regional enteritis (Crohn’s disease).

It also gives practical dosing notes (timing to reduce adrenal suppression, dietary salt advice) and mentions high-dose regimens used in other conditions.

If you use prednisone for IBD, the label’s key points are: dosing is individualized; do not stop suddenly after long-term therapy; take in the morning when possible; monitor for side effects and adjust dose during stress. This summary is based on the FDA DailyMed label text and not on independent review or clinical guidance.

Keep In Mind

This is an FDA DailyMed drug-label (regulatory) record, not a clinical guideline. Labels summarize approved indications and safety/administration information; treatment decisions (including steroid-sparing strategies) should be made with your clinician. The label emphasizes individualized dosing and gradual tapering after long-term use.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source

Regulatory update Evidence type derived from source or registry metadata.

PublicationopenFDA

PublisherU.S. Food and Drug Administration

SponsorREMEDYREPACK INC.

Study typeDrug Label Update

Indexed viaopenFDA

Source typeRegulatory record

PublishedAug 20, 2026, 12:00 AM

Content availableRegulatory record

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.